dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

November 16, 2021: Immatics Biotechnologies GmbH

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

  • Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase
  • Immatics to initiate three expansion cohorts for IMA203 targeting PRAME: monotherapy, combination with checkpoint inhibitor, and next-generation ACT approach
  • Cash and cash equivalents as well as other financial assets of $200.6 million1 (€173.2 million) as of September 30, 2021, funding company operations into 2023

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021
November 16, 2021: Molecular Health GmbH
November 17, 2021: Cosmo Pharmaceuticals NV

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz